Overview

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2028-06-01

Target enrollment:

Participant gender:

Summary

This study will enroll 6 DLT evaluable subjects (up to 12 patients total) where we will evaluate feasibility and safety of adoptive cellular therapy combined with IDH1/2 inhibitors in patients with recurrent or progressive oligodendroglioma WHO grade 2 and WHO grade 3.

Phase:

PHASE1

Details

Lead Sponsor:

University of Florida

Collaborator:

Oligo Nation, Inc

Treatments:

Diphtheria-Tetanus Vaccine
Granulocyte-Macrophage Colony-Stimulating Factor